Outlook Therapeutics presents at EURETINA Congress on bevacizumab treatment.

Outlook Therapeutics will present at the 25th EURETINA Congress in Paris on September 3, 2025. The presentation, titled "Optimising the treatment of retinal disease," will be given by CEO Bob Jahr. The event is part of the EURETINA Innovation Spotlight.

Outlook Therapeutics (NASDAQ: OTLK), a biopharmaceutical company specializing in bevacizumab treatments for retina diseases, will present at the EURETINA Innovation Spotlight during the 25th EURETINA Congress. The presentation titled "Optimising the treatment of retinal disease" will be delivered by CEO Bob Jahr on September 3, 2025, at 16:10 PM CEST / 10:10 AM EDT in Paris, France.

The EURETINA Congress, which will take place from September 4-7, 2025, at the Palais des Congrès, Paris, is set to mark its 25th anniversary with a record number of attendees and abstract submissions. The event will feature lectures and panel discussions from industry leaders, regulatory authorities, and ophthalmic investors, providing a dynamic, collaborative environment to foster innovation within the retina community [2].

Outlook Therapeutics' presentation will focus on optimizing the standard of care for bevacizumab in the treatment of retinal diseases. The company's flagship product, LYTENAVA™ (bevacizumab gamma), is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. The product is currently undergoing clinical trials in the United States, with the goal of becoming the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD [1].

The EURETINA Innovation Spotlight, a pre-meeting event scheduled for September 3, 2025, will feature presentations from various biopharmaceutical companies, including Outlook Therapeutics. This event aims to highlight the latest advancements and innovations in the field of retinal diseases, providing a platform for companies to showcase their latest developments and engage with the retina community [2].

Investors and financial professionals interested in the EURETINA Congress and the Outlook Therapeutics presentation are encouraged to register for the event and attend the presentation to gain insights into the latest developments in the treatment of retinal diseases.

References:
[1] https://www.stocktitan.net/news/OTLK/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-keyraxjtd89i.html
[2] https://www.modernretina.com/view/euretina-innovation-spotlight-kickstarts-the-2025-congress-eis-paris-france-anat-loewenstein